[A22-134] Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) – Benefit assessment according to § 35a SGB
Last updated 03.04.2023
Project no.:
A22-134
Commission:
Commission awarded on 20.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children and adolescents with HIV-1 infection
Result of dossier assessment:
- Treatment-naive children and adolescents:
weighing at least 14 kg and aged 2 to < 6 years: added benefit not proven
weighing at least 14 kg and aged 6 to < 12 years: added benefit not proven
weighing at least 14 kg and aged 12 to < 18 years: added benefit not proven - Pretreated children and adolescents weighing at least 14 kg and aged 2 to < 18 years: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-43 | Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |